Update of drug-resistant tuberculosis treatment guidelines: A turning point

•A guideline update regarding drug-resistant tuberculosis (DR-TB) treatment has been recently published by World Health Organization.•6-month bedaquiline, pretomanid, linezolid (600 mg), and moxifloxacin (BPaLM) is recommended rather than 9-month or longer regimens in multi DR/rifampicin-resistant T...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of infectious diseases Ročník 130; s. S12 - S15
Hlavní autoři:	Vanino, Elisa, Granozzi, Bianca, Akkerman, Onno W., Munoz-Torrico, Marcela, Palmieri, Fabrizio, Seaworth, Barbara, Tiberi, Simon, Tadolini, Marina
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Canada Elsevier Ltd 01.05.2023 Elsevier
Témata:	Antitubercular Agents - pharmacology DR-TB treatment guidelines Extensively Drug-Resistant Tuberculosis - drug therapy Humans Longer regimens MDR/RR-TB Rifampin - pharmacology Shorter regimen Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Pulmonary - drug therapy Longer regimens Shorter regimen MDR/RR-TB DR-TB treatment guidelines
ISSN:	1201-9712, 1878-3511, 1878-3511
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	•A guideline update regarding drug-resistant tuberculosis (DR-TB) treatment has been recently published by World Health Organization.•6-month bedaquiline, pretomanid, linezolid (600 mg), and moxifloxacin (BPaLM) is recommended rather than 9-month or longer regimens in multi DR/rifampicin-resistant TB (MDR/RR-TB).•9-month regimen is suggested instead of longer regimens in fluoroquinolones-susceptible MDR/RR-TB.•18-month regimens remain a valid option if shorter regimens cannot be implemented.•Further studies to clarify the use of bedaquiline, pretomanid, and linezolid/BPaLM in special situations are needed. In December 2022 World Health Organization released a new treatment for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main novelty of this update is two new recommendations (i) a 6-month treatment regimen composed of bedaquiline, pretomanid, linezolid (600 mg), and moxifloxacin (BPaLM) is recommended in place of the 9-month or longer (18-month) regimens in MDR/RR-TB patients, now including extensive pulmonary TB and extrapulmonary TB (except TB involving central nervous system, miliary TB and osteoarticular TB); (ii) the use of the 9-month all-oral regimen rather than longer (18-months) regimen is suggested in patients with MDR/RR-TB and in whom resistance to fluoroquinolones has been excluded. Longer (18-month) treatments remain a valid option in all cases in which shorter regimens cannot be implemented due to intolerance, drug-drug interactions, extensively drug-resistant tuberculosis, extensive forms of extrapulmonary TB, or previous failure. The new guidelines represent a milestone in MDR/RR-TB treatment landscape, setting the basis for a shorter, all-oral, more acceptable, equitable, and patient-centered model for MDR/RR-TB management. However, some challenges remain to be addressed to allow full implementation of the new recommendations.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1201-9712 1878-3511 1878-3511
DOI:	10.1016/j.ijid.2023.03.013